At a recent international breast cancer academic conference, Professor Nicholas C. Turner from The Royal Marsden Hospital and the Institute of Cancer Research (ICR) in the UK presented the highly anticipated primary analysis results of the Phase III persevERA BC study. This study aimed to evaluate the efficacy and safety of a novel oral selective estrogen receptor degrader (SERD), Giredestrant (GIRE), in combination with the CDK4/6 inhibitor Palbociclib (PALBO), compared to the standard aromatase inhibitor (AI) Letrozole (LET) plus Palbociclib, in the first-line treatment of estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).01 Background and Mechanism: Can Oral SERDs Reshape the First-Line Endocrine Therapy Landscape?
Endocrine therapy combined with a CDK4/6 inhibitor (CDK4/6i) is currently the standard of care (SoC) for the first-line treatment of ER+/HER2- advanced breast cancer. However, acquired resistance (such as ESR1 mutations) limits the long-term benefits of aromatase inhibitors. Giredestrant is a potent, next-generation non-steroidal oral SERD with robust estrogen receptor (ER) antagonistic effects, capable of deep and sustained inhibition of ER signaling. Previous findings in the lidERA study and other Phase II clinical explorations have shown Giredestrant’s potential in adjuvant therapy and later-line treatment for advanced disease, outperforming standard endocrine therapy (ET). The persevERA BC study is the first large-scale study in a first-line population to challenge the “gold standard” status of the “AI + CDK4/6i” oral SERD combination regimen. Professor Nicholas C. Turner pointed out that the core goal of this study was to explore whether replacing AI with a more potent ER degrader on the foundation of CDK4/6 inhibitors could bring more durable survival benefits to first-line patients with advanced disease.
02 Study Design: A Global Multicenter, Double-Blind, Randomized Controlled Phase III Trial
The persevERA BC study enrolled 992 patients with ER+/HER2- LA/mBC who had not previously received systemic therapy for advanced disease. Participants were randomized 1:1 into the following two groups: • Experimental Group: Giredestrant (30 mg/d, oral) + Palbociclib (125 mg/d, 3 weeks on, 1 week off) + Placebo (matching Letrozole). • Control Group: Letrozole (2.5 mg/d, oral) + Palbociclib (125 mg/d, 3 weeks on, 1 week off) + Placebo (matching Giredestrant). Stratification factors for the study included site of disease (visceral vs. non-visceral involvement), menopausal status (pre/perimenopausal vs. postmenopausal), geographic region, and treatment-free interval (TFI). The primary endpoint was investigator-assessed progression-free survival (PFS, based on RECIST v1.1 criteria). Secondary endpoints included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DoR), and safety. The study prespecified a primary analysis to be conducted when approximately 620 PFS events were observed. Adjusted for interim analysis, the P-value threshold for statistical significance was set at 0.0456, with a prespecified hazard ratio (HR) threshold of 0.85.
03 PFS Result Analysis: Numerical Improvement and Statistical Regret
At a median follow-up time of 52 months, Professor Nicholas C. Turner announced the following core efficacy data: • Median PFS Data: 33.1 months for the Giredestrant group and 28.2 months for the Letrozole group. • Hazard Ratio (HR): Stratified HR of 0.89 (95% CI: 0.77–1.03). • Statistical Evaluation: Although the median PFS in the Giredestrant group was numerically extended by 4.9 months, the calculated P-value was 0.1553, failing to reach the prespecified threshold for statistical significance (P < 0.0456). In interpreting the survival curves, Professor Nicholas C. Turner emphasized that the two curves almost completely overlapped during the first 12 months of treatment, but began to separate after 12 months, showing the potential benefit advantage of the Giredestrant group in long-term treatment. This “late separation” phenomenon suggests that for a first-line treatment population, a novel SERD may require more time to demonstrate its advantage in overcoming resistant clones.
04 Subgroup Analysis and Secondary Endpoints: Exploration of Visceral Involvement and Depth of Remission
In the prespecified subgroup analysis, results for most subgroups remained consistent with the overall population. • Treatment-Free Interval (TFI): For patients who relapsed after previous tamoxifen therapy (TFI > 12 months), the HR was 1.04; however, due to sample size limitations, the confidence interval was wide. • Disease Burden: Approximately 60% of patients had visceral disease, while only 9% had bone-only metastasis. In the population with visceral involvement, Giredestrant showed a robust numerical benefit. • Remission Status: The ORR of the two groups was very similar, with 60.2% in the Giredestrant group and 58.8% in the Letrozole group; the CBR was also basically the same. • Duration of Response (DoR): Notably, the median DoR in the Giredestrant group showed a clear numerical advantage, reaching 38.5 months, compared to 30.4 months in the Letrozole group—an extension of 8.1 months. This result further supports Giredestrant’s potential in maintaining long-term response. Regarding Overall Survival (OS), the data is currently immature (median follow-up of 52.2 months). Preliminary analysis shows an HR of 1.03 (95% CI: 0.84–1.27), and neither group has reached the median OS. Professor Turner pointed out that the first-line median survival for modern ER+/HER2- advanced breast cancer has exceeded 5 years, and more time is needed to observe survival benefits.
05 Safety Characteristics: A Well-Managed Risk Profile and Focus on Heart Rate
In terms of safety, Giredestrant combined with Palbociclib was generally well-tolerated, with no unexpected safety signals. • Dose Intensity: The median dose intensity in the Giredestrant group was 98.2%, comparable to the Letrozole group (98.9%). • Serious Adverse Events (SAEs): The incidence of SAEs was 23.9% in the Giredestrant group and 18.8% in the Letrozole group. • AEs Leading to Discontinuation: The rate of adverse events leading to treatment discontinuation was low in the Giredestrant group at 6.5%, compared to 5.5% in the Letrozole group. • Characteristic AE—Bradycardia: The Giredestrant group reported a bradycardia rate of 11.7%, significantly higher than the 1.8% in the Letrozole group. However, Professor Turner clarified that the vast majority of bradycardia events were asymptomatic (Grade 1 or 2). Among 494 subjects, only 2 (0.4%) reported symptomatic bradycardia, and safety was overall manageable. • Routine AEs: The incidence of Neutropenia was similar between the two groups, primarily attributed to the combined use of the CDK4/6 inhibitor Palbociclib.
06 Conclusions and Outlook: The PIONEERA Study Opens a New Chapter in Precision Medicine
Although the persevERA BC study did not reach statistical significance for its primary endpoint of PFS in the overall first-line population, Professor Nicholas C. Turner concluded that the study demonstrated the activity and safety of the oral SERD Giredestrant in first-line treatment for advanced disease, showing a positive numerical trend in long-term response maintenance. Regarding future directions, Professor Turner stated that the research team is shifting its focus to more precise beneficiary populations. The ongoing PIONEERA study is currently evaluating the efficacy of Giredestrant compared to Fulvestrant in combination with CDK4/6 inhibitors in patients who relapse during or within 12 months of completing adjuvant endocrine therapy. Such patients often have a higher risk of ESR1 mutations or primary endocrine resistance characteristics, where oral SERDs may demonstrate more significant clinical value.
Expert Summary:
The persevERA BC study provides valuable first-line data for oral SERDs challenging traditional AI therapy. Although the result of “numerical extension but statistical non-significance” reflects the high efficacy of current first-line treatments and the solid position of the existing SoC, Giredestrant’s advantage in DoR and its good safety profile lay the academic foundation for its further application under precise molecular subtyping. Clinical practice in China and globally still looks forward to subsequent studies like PIONEERA to provide solid evidence-based medical support for “de-AI” strategies in ER+ advanced breast cancer.
